JP2010284506A - バナジン酸イオン(VO43−)固溶β型リン酸三カルシウムからなる生体用セラミックス及びその製造方法 - Google Patents
バナジン酸イオン(VO43−)固溶β型リン酸三カルシウムからなる生体用セラミックス及びその製造方法 Download PDFInfo
- Publication number
- JP2010284506A JP2010284506A JP2010048297A JP2010048297A JP2010284506A JP 2010284506 A JP2010284506 A JP 2010284506A JP 2010048297 A JP2010048297 A JP 2010048297A JP 2010048297 A JP2010048297 A JP 2010048297A JP 2010284506 A JP2010284506 A JP 2010284506A
- Authority
- JP
- Japan
- Prior art keywords
- vanadate
- tricalcium phosphate
- tcp
- sintered body
- ion
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 title claims abstract description 116
- -1 vanadic acid ion Chemical class 0.000 title claims abstract description 100
- 235000019731 tricalcium phosphate Nutrition 0.000 title claims abstract description 44
- 239000001506 calcium phosphate Substances 0.000 title claims abstract description 42
- 229910000391 tricalcium phosphate Inorganic materials 0.000 title claims abstract description 42
- 229940078499 tricalcium phosphate Drugs 0.000 title claims abstract description 42
- 238000004519 manufacturing process Methods 0.000 title claims description 13
- 239000003462 bioceramic Substances 0.000 title abstract description 14
- 238000001354 calcination Methods 0.000 claims description 38
- 239000000919 ceramic Substances 0.000 claims description 34
- 238000000034 method Methods 0.000 claims description 33
- 238000000465 moulding Methods 0.000 claims description 13
- 239000002904 solvent Substances 0.000 claims description 13
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims description 12
- 239000000203 mixture Substances 0.000 claims description 11
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 11
- 238000010304 firing Methods 0.000 claims description 10
- 238000002156 mixing Methods 0.000 claims description 10
- 230000008569 process Effects 0.000 claims description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 6
- UNTBPXHCXVWYOI-UHFFFAOYSA-O azanium;oxido(dioxo)vanadium Chemical compound [NH4+].[O-][V](=O)=O UNTBPXHCXVWYOI-UHFFFAOYSA-O 0.000 claims description 6
- 229910000019 calcium carbonate Inorganic materials 0.000 claims description 6
- 239000000843 powder Substances 0.000 claims description 6
- XAAHAAMILDNBPS-UHFFFAOYSA-L calcium hydrogenphosphate dihydrate Chemical compound O.O.[Ca+2].OP([O-])([O-])=O XAAHAAMILDNBPS-UHFFFAOYSA-L 0.000 claims description 5
- 235000019700 dicalcium phosphate Nutrition 0.000 claims description 5
- 238000007580 dry-mixing Methods 0.000 claims description 5
- 238000010298 pulverizing process Methods 0.000 claims description 5
- 239000008187 granular material Substances 0.000 claims description 3
- 238000000227 grinding Methods 0.000 claims 1
- 229940085991 phosphate ion Drugs 0.000 claims 1
- 239000006104 solid solution Substances 0.000 abstract description 44
- 210000000988 bone and bone Anatomy 0.000 abstract description 23
- 239000000463 material Substances 0.000 abstract description 19
- 239000013078 crystal Substances 0.000 abstract description 17
- 239000002245 particle Substances 0.000 abstract description 9
- 238000010521 absorption reaction Methods 0.000 abstract description 8
- 239000000126 substance Substances 0.000 abstract description 6
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 abstract description 4
- 229910000147 aluminium phosphate Inorganic materials 0.000 abstract description 2
- 230000007547 defect Effects 0.000 abstract description 2
- 239000000243 solution Substances 0.000 abstract description 2
- 238000006467 substitution reaction Methods 0.000 abstract description 2
- 239000011575 calcium Substances 0.000 description 37
- LEONUFNNVUYDNQ-UHFFFAOYSA-N vanadium atom Chemical compound [V] LEONUFNNVUYDNQ-UHFFFAOYSA-N 0.000 description 28
- 229910052720 vanadium Inorganic materials 0.000 description 27
- 238000005452 bending Methods 0.000 description 22
- 230000001965 increasing effect Effects 0.000 description 18
- 238000002441 X-ray diffraction Methods 0.000 description 17
- 230000008859 change Effects 0.000 description 14
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 13
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 13
- 230000000694 effects Effects 0.000 description 12
- 238000010586 diagram Methods 0.000 description 10
- 239000013642 negative control Substances 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 9
- 238000005245 sintering Methods 0.000 description 9
- 238000005259 measurement Methods 0.000 description 8
- 210000000963 osteoblast Anatomy 0.000 description 8
- 239000013641 positive control Substances 0.000 description 8
- 229910001456 vanadium ion Inorganic materials 0.000 description 8
- 229910019142 PO4 Inorganic materials 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 7
- 239000012071 phase Substances 0.000 description 7
- 239000010452 phosphate Substances 0.000 description 7
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 239000006227 byproduct Substances 0.000 description 6
- 238000011156 evaluation Methods 0.000 description 6
- 230000011164 ossification Effects 0.000 description 6
- 239000002994 raw material Substances 0.000 description 6
- 238000003786 synthesis reaction Methods 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- LSGOVYNHVSXFFJ-UHFFFAOYSA-N vanadate(3-) Chemical compound [O-][V]([O-])([O-])=O LSGOVYNHVSXFFJ-UHFFFAOYSA-N 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 4
- 238000001157 Fourier transform infrared spectrum Methods 0.000 description 4
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 4
- 102000013275 Somatomedins Human genes 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 229910052791 calcium Inorganic materials 0.000 description 4
- 230000005757 colony formation Effects 0.000 description 4
- 238000013329 compounding Methods 0.000 description 4
- 231100000263 cytotoxicity test Toxicity 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 229910021645 metal ion Inorganic materials 0.000 description 4
- 229920006395 saturated elastomer Polymers 0.000 description 4
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 230000001332 colony forming effect Effects 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 150000002500 ions Chemical class 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- BOXSVZNGTQTENJ-UHFFFAOYSA-L zinc dibutyldithiocarbamate Chemical compound [Zn+2].CCCCN(C([S-])=S)CCCC.CCCCN(C([S-])=S)CCCC BOXSVZNGTQTENJ-UHFFFAOYSA-L 0.000 description 3
- 238000007088 Archimedes method Methods 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical group [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 210000002805 bone matrix Anatomy 0.000 description 2
- JUNWLZAGQLJVLR-UHFFFAOYSA-J calcium diphosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])(=O)OP([O-])([O-])=O JUNWLZAGQLJVLR-UHFFFAOYSA-J 0.000 description 2
- 229940043256 calcium pyrophosphate Drugs 0.000 description 2
- 229910010293 ceramic material Inorganic materials 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 235000019821 dicalcium diphosphate Nutrition 0.000 description 2
- 238000005530 etching Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 229910001425 magnesium ion Inorganic materials 0.000 description 2
- VSIIXMUUUJUKCM-UHFFFAOYSA-D pentacalcium;fluoride;triphosphate Chemical compound [F-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O VSIIXMUUUJUKCM-UHFFFAOYSA-D 0.000 description 2
- 229920006264 polyurethane film Polymers 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 2
- 235000012239 silicon dioxide Nutrition 0.000 description 2
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 239000012085 test solution Substances 0.000 description 2
- 239000011573 trace mineral Substances 0.000 description 2
- 235000013619 trace mineral Nutrition 0.000 description 2
- RKQOSDAEEGPRER-UHFFFAOYSA-L zinc diethyldithiocarbamate Chemical compound [Zn+2].CCN(CC)C([S-])=S.CCN(CC)C([S-])=S RKQOSDAEEGPRER-UHFFFAOYSA-L 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 108091006112 ATPases Proteins 0.000 description 1
- 102000057290 Adenosine Triphosphatases Human genes 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 102000018997 Growth Hormone Human genes 0.000 description 1
- 108010051696 Growth Hormone Proteins 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- WCVKJPBMXOEQQP-UHFFFAOYSA-L O.O.P(=O)(O)([O-])OCC.[Ca+2].C(C)OP(=O)(O)[O-] Chemical compound O.O.P(=O)(O)([O-])OCC.[Ca+2].C(C)OP(=O)(O)[O-] WCVKJPBMXOEQQP-UHFFFAOYSA-L 0.000 description 1
- 102000004338 Transferrin Human genes 0.000 description 1
- 108090000901 Transferrin Proteins 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- PTFCDOFLOPIGGS-UHFFFAOYSA-N Zinc dication Chemical compound [Zn+2] PTFCDOFLOPIGGS-UHFFFAOYSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229910052586 apatite Inorganic materials 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000003305 autocrine Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 238000012925 biological evaluation Methods 0.000 description 1
- 230000033558 biomineral tissue development Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000002449 bone cell Anatomy 0.000 description 1
- 239000002639 bone cement Substances 0.000 description 1
- 230000037182 bone density Effects 0.000 description 1
- 230000002308 calcification Effects 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 239000004068 calcium phosphate ceramic Substances 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 238000005467 ceramic manufacturing process Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000001955 cumulated effect Effects 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 238000000280 densification Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000000151 deposition Methods 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000006377 glucose transport Effects 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 229920006262 high density polyethylene film Polymers 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000008676 import Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000002608 insulinlike Effects 0.000 description 1
- 238000010813 internal standard method Methods 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 239000003758 nuclear fuel Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000003076 paracrine Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 238000013001 point bending Methods 0.000 description 1
- 238000005498 polishing Methods 0.000 description 1
- 230000007542 postnatal development Effects 0.000 description 1
- 230000009596 postnatal growth Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000004451 qualitative analysis Methods 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 239000012925 reference material Substances 0.000 description 1
- 238000001028 reflection method Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000012958 reprocessing Methods 0.000 description 1
- 238000011076 safety test Methods 0.000 description 1
- 238000009781 safety test method Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000011863 silicon-based powder Substances 0.000 description 1
- 229910001415 sodium ion Inorganic materials 0.000 description 1
- 229940054269 sodium pyruvate Drugs 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 238000003746 solid phase reaction Methods 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 238000004544 sputter deposition Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000041 toxicology testing Toxicity 0.000 description 1
- 239000012581 transferrin Substances 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Landscapes
- Materials For Medical Uses (AREA)
- Dental Preparations (AREA)
Abstract
【解決手段】β型リン酸三カルシウムのリン酸サイトにバナジン酸イオン(VO4 3-)を置換固溶したβ型リン酸三カルシウムからなる生体用セラミックスを提供する。
【選択図】図11
Description
<<実施形態>>
<実施形態:概要>
<実施形態:構成>
[表1]
<実施形態:効果>
[表2]
[表3]
[表4]
[表5]
Claims (8)
- バナジン酸イオン(VO4 3-)を固溶したβ型リン酸三カルシウムからなる生体用セラミックス。
- リン酸イオン(PO4 3-)に対して20mol%以下のバナジン酸イオン(VO4 3-)を固溶した請求項1に記載のβ型リン酸三カルシウムからなる生体用セラミックス。
- リン酸水素カルシウム二水和物と炭酸カルシウムとバナジン酸アンモニウムを乾式混合し、得られた混合物を焼成して合成される請求項1または2のいずれか一に記載のβ型リン酸三カルシウムからなる生体用セラミックス。
- 請求項1から3のいずれか一に記載のβ型リン酸三カルシウムの焼結体からなる生体用セラミックス。
- 請求項1から3のいずれか一に記載の生体用セラミックスであって、その性状が粉体である生体用セラミックス。
- 請求項1から3のいずれか一に記載の生体用セラミックスであって、その性状が顆粒体である生体用セラミックス。
- 請求項1から3のいずれか一に記載の生体用セラミックスであって、その性状が膜状である生体用セラミックス。
- リン酸水素カルシウム二水和物と炭酸カルシウムとバナジン酸アンモニウムとを湿式混合した後、得られた混合物から溶媒エタノールを除去する混合工程と、
混合工程で得られた混合体を溶媒中で粉砕した後、前記溶媒を除去する粉砕工程と、
粉砕工程で得られた粉体を一軸加圧成型して成型体を作成する成型工程と、
成型工程で得られた成型体を焼成する焼成工程と、
を有する請求項4に記載のβ型リン酸三カルシウム焼結体を製造するβ型リン酸三カルシウム焼結体製造方法。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2010048297A JP5681968B2 (ja) | 2009-05-12 | 2010-03-04 | バナジン酸イオン(VO43−)固溶β型リン酸三カルシウムからなる生体用セラミックス及びその製造方法 |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2009115850 | 2009-05-12 | ||
JP2009115850 | 2009-05-12 | ||
JP2010048297A JP5681968B2 (ja) | 2009-05-12 | 2010-03-04 | バナジン酸イオン(VO43−)固溶β型リン酸三カルシウムからなる生体用セラミックス及びその製造方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2010284506A true JP2010284506A (ja) | 2010-12-24 |
JP5681968B2 JP5681968B2 (ja) | 2015-03-11 |
Family
ID=43540670
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2010048297A Active JP5681968B2 (ja) | 2009-05-12 | 2010-03-04 | バナジン酸イオン(VO43−)固溶β型リン酸三カルシウムからなる生体用セラミックス及びその製造方法 |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP5681968B2 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017038647A1 (ja) * | 2015-08-28 | 2017-03-09 | 株式会社福山医科 | 代用骨ブロック、代用骨ブロックの製造方法 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2000302567A (ja) * | 1999-04-13 | 2000-10-31 | Toshiba Ceramics Co Ltd | リン酸カルシウム系多孔質焼結体およびその製造方法 |
-
2010
- 2010-03-04 JP JP2010048297A patent/JP5681968B2/ja active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2000302567A (ja) * | 1999-04-13 | 2000-10-31 | Toshiba Ceramics Co Ltd | リン酸カルシウム系多孔質焼結体およびその製造方法 |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017038647A1 (ja) * | 2015-08-28 | 2017-03-09 | 株式会社福山医科 | 代用骨ブロック、代用骨ブロックの製造方法 |
Also Published As
Publication number | Publication date |
---|---|
JP5681968B2 (ja) | 2015-03-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Kim et al. | Pressureless sintering and mechanical and biological properties of fluor‐hydroxyapatite composites with zirconia | |
Zhu et al. | 3D plotting of highly uniform Sr 5 (PO 4) 2 SiO 4 bioceramic scaffolds for bone tissue engineering | |
Tian et al. | Novel Co-akermanite (Ca 2 CoSi 2 O 7) bioceramics with the activity to stimulate osteogenesis and angiogenesis | |
Srigurunathan et al. | Unveiling the effects of rare-earth substitutions on the structure, mechanical, optical, and imaging features of ZrO2 for biomedical applications | |
CN110272271B (zh) | 一种微量锰掺杂羟基磷灰石生物陶瓷粉体材料及其制备方法和应用 | |
Cama et al. | The role of new zinc incorporated monetite cements on osteogenic differentiation of human mesenchymal stem cells | |
Lin et al. | High mechanical strength bioactive wollastonite bioceramics sintered from nanofibers | |
FU et al. | Zirconia incorporation in 3D printed β-Ca2SiO4 scaffolds on their physicochemical and biological property | |
Carbajal et al. | Role of ZnO additions on the β/α phase relation in TCP based materials: Phase stability, properties, dissolution and biological response | |
Ponnilavan et al. | Structural and bio-mineralization features of alumina zirconia composite influenced by the combined Ca2+ and PO43− additions | |
Nandha Kumar et al. | Formation mechanisms in β-Ca3 (PO4) 2–ZnO composites: structural repercussions of composition and heat treatments | |
Singh et al. | Synthesis and characterization of bioactive zirconia toughened alumina doped with HAp and fluoride compounds | |
Myat-Htun et al. | Tailoring mechanical and in vitro biological properties of calcium‒silicate based bioceramic through iron doping in developing future material | |
He et al. | Synthesis, characterization and cell response of silicon/gallium co-substituted tricalcium phosphate bioceramics | |
TW200934461A (en) | Calcium silicate-based cements and manufacturing method thereof | |
JP6035627B2 (ja) | β型リン酸三カルシウムからなる生体材料 | |
JP5681968B2 (ja) | バナジン酸イオン(VO43−)固溶β型リン酸三カルシウムからなる生体用セラミックス及びその製造方法 | |
JP6109773B2 (ja) | 生体材料セラミックス焼結体及びその製造方法 | |
Ghosh et al. | Study on the development of machinable hydroxyapatite-yttrium phosphate composite for biomedical applications | |
Zhang et al. | Improving the osseointegration and soft tissue sealing of zirconia ceramics by the incorporation of akermanite via sol infiltration for dental implants | |
JP2011229854A (ja) | β型リン酸三カルシウムからなる生体材料セラミックス及びその製造方法 | |
JP6035623B2 (ja) | 三価金属イオンの固溶量によるリン酸三カルシウムからなる生体材料セラミックスの溶解性及び焼結性の制御方法 | |
CN106904954B (zh) | 一种具有生物活性的陶瓷材料、制备方法及其应用 | |
Denry et al. | Crystalline phase evolution and thermal behavior of zirconia‐lanthanum aluminate ceramics produced by surface modification | |
Jabri et al. | Synthesis and Antibacterial Study of New Microporous Zinc Phosphate Bioceramics |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20130226 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20140407 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140530 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20140908 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20141002 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20141218 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5681968 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |